Trial Profile
Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Dasatinib; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 24 Jan 2013 New trial record